Context Capital Management LLC Makes New $464,000 Investment in Karyopharm Therapeutics Inc. $KPTI

Context Capital Management LLC bought a new position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 62,995 shares of the company’s stock, valued at approximately $464,000. Context Capital Management LLC owned approximately 0.34% of Karyopharm Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of KPTI. XTX Topco Ltd acquired a new position in Karyopharm Therapeutics in the 2nd quarter worth about $56,000. Baird Financial Group Inc. acquired a new stake in shares of Karyopharm Therapeutics in the second quarter valued at about $45,000. Bank of America Corp DE increased its stake in shares of Karyopharm Therapeutics by 26.8% in the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after buying an additional 35,626 shares during the period. Bridgeway Capital Management LLC acquired a new stake in shares of Karyopharm Therapeutics in the second quarter valued at about $163,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Karyopharm Therapeutics in the third quarter valued at about $164,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Rodman & Renshaw raised Karyopharm Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 10th. Piper Sandler reissued an “overweight” rating and issued a $16.00 price target (up from $8.00) on shares of Karyopharm Therapeutics in a research note on Monday, April 27th. HC Wainwright increased their price target on Karyopharm Therapeutics from $8.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Robert W. Baird decreased their price target on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating for the company in a research note on Wednesday, March 25th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Karyopharm Therapeutics in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Karyopharm Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $17.17.

Karyopharm Therapeutics Price Performance

NASDAQ KPTI opened at $9.50 on Friday. The business has a 50 day simple moving average of $8.47 and a 200 day simple moving average of $7.67. Karyopharm Therapeutics Inc. has a one year low of $3.65 and a one year high of $10.99. The stock has a market capitalization of $215.30 million, a P/E ratio of -0.63 and a beta of 0.83.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, May 14th. The company reported ($1.24) EPS for the quarter, topping the consensus estimate of ($1.45) by $0.21. The business had revenue of $35.07 million for the quarter, compared to analyst estimates of $31.40 million. Equities analysts expect that Karyopharm Therapeutics Inc. will post -3.24 earnings per share for the current year.

Karyopharm Therapeutics Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.